BioNTech Update on CureVac Share Offer, Dec. 3 Expiration
BioNTech’s tender offer for CureVac cleared a key hurdle after CureVac shareholders approved the deal-related proposals at a November...
Scilex Finalizes Two-Tranche Equity Financing in DataVault
Scilex Holding Company has closed the second tranche of its strategic investment in Datavault AI, exercising a pre-funded warrant...
New Leqembi Drug App for Alzheimer’s Disease in Japan
Eisai has filed a new drug application with Japan’s PMDA for a subcutaneous autoinjector formulation of lecanemab (Leqembi), seeking...
Pacira Files Exparel® Patent Infringement Lawsuits
Pacira BioSciences has filed patent infringement suits in Delaware against Whiteoak Group and Qilu Pharmaceutical over proposed generic versions...
Valneva Announces Positive Final Lyme Vaccine Phase 2 Data
Valneva reported positive final Phase 2 immunogenicity and safety data for VLA15, the Pfizer-partnered Lyme disease vaccine, showing robust...
Valneva Announces Positive Phase 2 Results for Lyme Vaccine
Valneva reported final Phase 2 immunogenicity and safety data for VLA15, the multivalent Lyme disease vaccine co-developed with Pfizer,...
BiomX Update on BX004 Phase 2b Cystic Fibrosis Trial
BiomX’s Phase 2b trial of BX004, an inhaled phage cocktail targeting Pseudomonas aeruginosa in cystic fibrosis, remains under an...
Clairity, Myriad, MagView Launch AI Genetic Risk Platform
Clairity, Myriad Genetics, and MagView have formed a collaboration to integrate genotype and phenotype breast cancer risk assessment directly...
Scilex’s Successful Warrant Exercise Unlocks Sizable $20.3M
Scilex Holding Company has closed a warrant inducement financing that pulls in approximately $20.3 million in gross proceeds. The...
Onco360 Selected as National Partner for Hyruno® (sevabertinib)
Bayer has secured FDA accelerated approval for Hyrnuo (sevabertinib), a reversible HER2 tyrosine kinase inhibitor, for adults with locally...